A network meta-analysis of 21,745 patients found high-dose diuretics best reduced NT-proBNP levels while levosimendan best improved kidney function in acute heart failure with renal dysfunction, with nesiritide showing no superiority.
21,745 patients across 13 trialsHigh-dose diuretics best reduced the heart failure biomarker NT-proBNP, while levosimendan best improved kidney function — nesiritide showed no superiority
What the researchers found
Across 13 studies (21,745 patients), the network meta-analysis compared nesiritide, dopamine, tolvaptan, levosimendan, dobutamine, furosemide, spirolactone, and high-dose diuretics (HDD).
Key results:
- HDD had the best efficacy in reducing NT-proBNP levels, with a mean difference of -950.24 (95% CrI: -1,832.21 to -64.12) compared to placebo/conventional treatment.
- Levosimendan significantly improved GFR compared to placebo (MD = 14.46; 95% CrI: 3.88 to 25.97) and tolvaptan (MD = 13.83; 95% CrI: 2.31 to 25.33).
- No significant differences were found in 60-day all-cause mortality or cardiovascular mortality across all drugs.
- Nesiritide did not demonstrate superior efficacy compared to other treatments in this population.
Why it matters
Acute heart failure with kidney dysfunction is common and carries high mortality. This analysis provides the first comprehensive network comparison of multiple drug classes in this specific population, helping clinicians identify optimal treatments. The finding that the peptide drug nesiritide did not outperform alternatives is particularly relevant given its cost and prior controversy.
How the study worked
This was a systematic review and network meta-analysis searching PubMed, EMBASE, Cochrane Library, and Web of Science for clinical trials of acute heart failure drugs published between 2001 and March 2024. From 30,697 citations screened, 13 studies with 21,745 patients were included. Primary outcomes included NT-proBNP, BNP, GFR, blood urea nitrogen, serum creatinine, 60-day all-cause mortality, and cardiovascular mortality. The study was pre-registered on PROSPERO.
What this study cannot tell us
The included studies varied in design, drug doses, follow-up periods, and patient populations, which may affect comparisons. The network meta-analysis relies on indirect comparisons for many drug pairs. Only 13 studies met inclusion criteria, and some drug comparisons had limited data. The 60-day mortality endpoint may be too short to capture meaningful survival differences.
How to read the evidence
This is a systematic review and network meta-analysis of clinical trials, representing a high level of evidence. However, the reliance on indirect comparisons and heterogeneity across studies introduces some uncertainty.
When this study was published
Published in 2024 with studies searched through March 2024, this represents the most current comprehensive comparison of drugs for acute heart failure with renal dysfunction.
The bigger picture
Nesiritide, a recombinant B-type natriuretic peptide, was once widely used for acute heart failure but fell out of favor after trials showed it didn't improve mortality and may worsen kidney function. This meta-analysis confirms that other agents — particularly high-dose diuretics and levosimendan — appear more effective in the specific population of heart failure patients with kidney problems.
Questions still open
- Should nesiritide still have a role in treating acute heart failure with renal dysfunction given its lack of superiority?
- Would combining levosimendan with high-dose diuretics provide additive benefit for both cardiac and renal outcomes?
- Are newer natriuretic peptide-based therapies more effective than nesiritide in this population?
Common questions
What is nesiritide and why is it relevant to peptide research?
What treatment works best for heart failure patients with kidney problems?
Read the original research
Comparative efficacy of different drugs in acute heart failure with renal dysfunction: a systematic review and network meta-analysis.
Frontiers in cardiovascular medicine, 11, 1444068
Citation
Lv, Qianyu; Wu, Qian; Yang, Yingtian; Li, Lanlan; Ye, Xuejiao; Wang, Shihan; Lv, Yanfei; Wang, Manshi; Li, Yushan. (2024). Comparative efficacy of different drugs in acute heart failure with renal dysfunction: a systematic review and network meta-analysis.. Frontiers in cardiovascular medicine, 11, 1444068. https://doi.org/10.3389/fcvm.2024.1444068